Schedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Schedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8"

Transcription

1 Carboplatin/Gemcitabine Lung Cancer (non-small cell) - Advanced Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Cycle frequency: Every three weeks Total number of cycles: 4 Anti-emetic group Moderately high Carboplatin dose by EDTA or creatinine clearance. If calculated using formula then AUC 6 vomiting, mucositis, alopecia (uncommon), amenorrhoea, peripheral neuropathy, diarrhoea, carcinogenesis, infertility Symptomatic treatment of side effects: Mouth care, CXR U & E s, LFTs, creatinine, urate, creatinine clearance U & E s, LFTs, creatinine After two cycles Reference: Rudd et al, J. Clin. Oncol., 23; pages rd Edition 1

2 Cisplatin/Gemcitabine Lung Cancer (non-small cell) Adjuvant, Neoadjuvant Cisplatin 50mg/m 2 1L N. Saline/2hrs Day 1, 2 Gemcitabine 1250mg/m 2 200mls N. Saline/30mins Days 1 & 8 Cycle frequency: Every three weeks Total number of cycles: 4 Anti-emetic group High Pre & post hydration, mannitol, potassium & magnesium vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, nephrotoxicity, ototoxicity, diarrhoea, carcinogenesis, infertility, CXR After two cycles Reference: Cardenal et al, J. Clin. Oncol., 17; pages rd Edition 2

3 Carboplatin/Vinorelbine Advanced Lung, Breast and Ovarian cancer Vinorelbine 25mg/m 2 20mls N. Saline/10mins Days 1 & 8 Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Cycle frequency: Every three weeks Total number of cycles: 4-6 Anti-emetic group Moderately high Carboplatin dose by EDTA or creatinine clearance. If calculated using formula then AUC 6 vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, fluid retention, hypersensitivity reaction, abdominal discomfort, infertility Symptomatic treatment of side effects: Mouth care, diuretics U & E s, LFTs, creatinine, urate, creatinine clearance U & E s, LFTs, creatinine Abdominal CT scan prior to fourth cycle if measurable disease present (ovarian) Reference: Cremonesi et al, Oncology, 64; pages rd Edition 3

4 MVP Lung Cancer (non-small cell) - Advanced, Palliative Mitomycin C 8mg/m 2 iv Day 1 Vinblastine 6mg/m 2 (max 10mg) iv Day 1 Cisplatin 50mg/m 2 1L N. Saline/2hrs Day 1 Cycle frequency: Every three weeks Total number of cycles: 3 Anti-emetic group High Ensure serum creatinine is within normal levels Pre & post hydration, mannitol, potassium & magnesium Blood film is normal i.e. no red cell fragmentation vomiting, mucositis, alopecia, cardiotoxicity, peripheral neuropathy, nephrotoxicity, ototoxicity, infertility, CXR Reference: Smith et al, J. Clin. Oncol., 19; pages rd Edition 4

5 MIC Lung Cancer (non-small cell) - Advanced, Palliative Mitomycin C 6mg/m 2 iv Day 1 Ifosfamide 3000mg/m 2 1L N. Saline/4hrs Day 1 Cisplatin 50mg/m 2 1L N. Saline/2hrs Day 1 Cycle frequency: Every three weeks Total number of cycles: 4 Anti-emetic group High Pre & post hydration, mannitol, potassium & magnesium Mesna dose guidelines vomiting, mucositis, alopecia, peripheral neuropathy, diarrhoea, constipation, nephrotoxicity, ototoxicity, encephalopathy, carcinogenesis, infertility, CXR Re-assess after 2 cycles Reference: Cullen et al, Br. J. Cancer, 58; pages rd Edition 5

6 NP (Vinorelbine/Cisplatin) Lung Cancer (non-small cell) Adjuvant Vinorelbine 30mg/m 2 20mls N. Saline/10mins Days 1, 8, 15 & 22 Cisplatin 50mg/m 2 1L N. Saline/4hrs Days 1 & 2 Cycle frequency: Every four weeks Total number of cycles: 4 Anti-emetic group High Pre & post hydration, mannitol, potassium & magnesium vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, nephrotoxicity, ototoxicity, diarrhoea, carcinogenesis, infertility, CXR Re-assess after 2 cycles Reference: Winton et al, N. Engl. J. Med., 352; pages rd Edition 6

7 Docetaxel Lung Cancer (non-small cell) - Recurrent Docetaxel 75mg/m 2 250mls N. Saline/1hr Day 1 Cycle frequency: Every three weeks Total number of cycles: 6 Anti-emetic group Low Pre-medication dexamethasone 8 mg bd oral, for three days, starting one day prior vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, fluid retention, hypersensitivity reaction, skin rash, infertility Symptomatic treatment of side effects: Mouth care, CXR U & E s, LFTs, creatinine, urate U & E s, LFTs, creatinine Re-assess after 2 cycles Reference: Shephard et al, J. Clin. Oncol., 18; pages rd Edition 7

8 Docetaxel/Cisplatin Lung Cancer (non-small cell) Advanced, Palliative Docetaxel 75mg/m 2 250ml N. Saline/1hr Day 1 Cisplatin 75mg/m 2 1L N. Saline/4hrs Day 1 Cycle frequency: Every three weeks Total number of cycles: 4 Anti-emetic group High Pre-medication dexamethasone 8mg bd oral, for three days, starting one day prior Pre & post hydration, mannitol, potassium & magnesium vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, nephrotoxicity, ototoxicity, diarrhoea, carcinogenesis, infertility, fluid retention, hypersensitivity reaction History and examination, CXR Mid-treatment: Post-treatment: Re-assess after 2 cycles Reference: Schiller et al, N. Engl. J. Med., 346; pages rd Edition 8

9 PE (Cisplatin/Etoposide) - long Lung Cancer (small cell) - Limited Cisplatin 60mg/m 2 1L N. Saline/2hrs Day 1 Etoposide 120mg/m 2 1L N. Saline/2hrs Days 1-3 Cycle frequency: Every three weeks Total number of cycles: 4 ( Anti-emetic group High Pre & post hydration, mannitol, potassium & magnesium vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, nephrotoxicity, ototoxicity, diarrhoea, carcinogenesis, infertility Re-assess prior to third cycle Reference: Turrisis et al, N. Engl. J. Med., 340; pages rd Edition 9

10 PE (Cisplatin/Etoposide) - short Lung Cancer (small cell) - Limited Cisplatin 60mg/m 2 1L N. Saline/2hrs Day 1 Etoposide 120mg/m 2 1L N. Saline/2hrs Day 1 Etoposide 100mg bd oral Days 2 & 3 Cycle frequency: Every three weeks Total number of cycles: 4 Anti-emetic group High Pre & post hydration, mannitol, potassium & magnesium vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, nephrotoxicity, ototoxicity, diarrhoea, carcinogenesis, infertility Re-assess prior to third cycle Reference: Evans et al, Ann. Intern. Med., 107; pages rd Edition 10

11 Carboplatin/Etoposide - long Lung Cancer - Advanced Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Etoposide 100mg/m 2 500mls N. Saline/2hrs Days 1-3 Cycle frequency: Every three weeks Total number of cycles: 4-6 Anti-emetic group Moderately high Etoposide 100mg bd oral may be substituted on days 2 & 3 Carboplatin dose by EDTA or creatinine clearance. If calculated using formula then AUC 6 vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, nephrotoxicity, diarrhoea, carcinogenesis, infertility Re-assess prior to third cycle Reference: Skarlos et al, Ann. Oncol., 5; pages rd Edition 11

12 Carboplatin/Etoposide - short Lung Cancer - Advanced Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Etoposide 100mg/m 2 500mls N. Saline/2hrs Day 1 Etoposide 100mg bd oral Days 2 & 3 Cycle frequency: Every three weeks Total number of cycles: 4-6 Anti-emetic group Moderately high Carboplatin dose by EDTA or creatinine clearance. If calculated using formula then AUC 6 vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, nephrotoxicity, diarrhoea, carcinogenesis, infertility Re-assess prior to third cycle Reference: Skarlos et al, Ann. Oncol., 5; pages rd Edition 12

13 CAV (Cyclophosphamide/Doxorubicin/Vincristine) Lung Cancer (small cell) Palliative Cyclophosphamide 1,000mg/m 2 iv Day 1 Doxorubicin 50mg/m 2 iv Day 1 Vincristine 1.4mg/m 2 (max 2mg) iv Day 1 Cycle frequency: Every three weeks Total number of cycles: 6 Anti-emetic group Moderately high vomiting, mucositis, alopecia, cardiotoxicity, amenorrhoea, peripheral neuropathy, haemorrhagic cystitis, constipation, carcinogenesis, infertility, CXR U & E s, LFTs, creatinine, urate U & E s, LFTs, creatinine Re-assess prior to fourth cycle Reference: Evans et al, Ann. Intern. Med., 107; pages rd Edition 13

14 Oral Etoposide Lung Cancer (small cell) - Palliative Etoposide 100mg od oral Days 1-10 (14) Cycle frequency: Every three weeks Total number of cycles: 6 Anti-emetic group Mild Start with 10 day course (total dose 1000 mg) Toxicities: Myelosuppression and risk of neutropenic sepsis or haemorrhage, nausea, mucositis, alopecia, carcinogenesis, infertility Symptomatic treatment of side effects: Mouth care, CXR U & E s, LFTs, creatinine, urate U & E s, LFTs, creatinine Re-assess after every two cycles Reference: Slevin, J. Clin. Oncol., 8; pages rd Edition 14

Cycle frequency: Every three weeks Total number of cycles: 6

Cycle frequency: Every three weeks Total number of cycles: 6 Carboplatin/Paclitaxel Ovarian Cancer Adjuvant, Advanced Paclitaxel 175mg/m 2 500mls 5% dex/3hrs Day 1 Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Anti-emetic group - Moderately high Paclitaxel given first

More information

Schedule: Drug Dose iv/infusion/oral q Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2

Schedule: Drug Dose iv/infusion/oral q Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2 Doxorubicin/Cisplatin Osteosarcoma - neoadjuvant Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2 (3 before surgery) Ensure adequate renal function Pre & post-hydration,

More information

Cycle frequency: Every three weeks Total number of cycles: 3 or 4

Cycle frequency: Every three weeks Total number of cycles: 3 or 4 BEP 3-day (Bleomycin/Etoposide/Cisplatin) Germ cell tumours Bleomycin 30,000iu 200mls N. Saline/30mins Days 2, 8 & 15 Etoposide 165mg/m 2 1L N. Saline/1hr Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/4hrs

More information

Cycle frequency: Every four weeks Total number of cycles: 6-8

Cycle frequency: Every four weeks Total number of cycles: 6-8 Fludarabine Low Grade non-hodgkin s Lymphoma and CLL Fludarabine 25mg/m 2 oral Days 1-5 Cycle frequency: Every four weeks Total number of cycles: 6-8 Anti-emetic group Low Prophylactic co-trimoxazole and

More information

Cycle frequency: Every three weeks Total number of cycles: 4 (Adjuvant) 6 (Palliative)

Cycle frequency: Every three weeks Total number of cycles: 4 (Adjuvant) 6 (Palliative) AC (Doxorubicin/Cyclophosphamide) Breast Cancer Adjuvant, Palliative Doxorubicin 60mg/m 2 iv Day 1 Cyclophosphamide 600mg/m 2 iv Day 1 Cycle frequency: Every three weeks Total number of cycles: 4 (Adjuvant)

More information

Network Chemotherapy Regimens

Network Chemotherapy Regimens Network Chemotherapy Regimens Lung Cancer Notes from the editor Thames Valley Cancer Network These protocols are available on the Network website www.tvcn.org.uk. Any correspondence about the protocols

More information

Chapter 7: Lung Cancer

Chapter 7: Lung Cancer Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin

More information

Lymphoblastic Lymphoma Burkitt s Lymphoma. Core: Standard therapy; a regimen widely used by most Regional Cancer Centres in this disease site

Lymphoblastic Lymphoma Burkitt s Lymphoma. Core: Standard therapy; a regimen widely used by most Regional Cancer Centres in this disease site A REGIMEN NAME MAGRATH PROTOCOL Chemotherapy Cancer Lymphoblastic Lymphoma Burkitt s Lymphoma Curative Intent Regimen Category Rationale and Indication Core: Standard therapy; a regimen widely used by

More information

Lung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC) Indication: NICE TA181 First line treatment option in advanced or metastatic non-squamous NSCLC (histology confirmed as adenocarcinoma or large cell carcinoma) Performance status 0-1 Regimen details: Pemetrexed

More information

Thames Valley Chemotherapy Regimens

Thames Valley Chemotherapy Regimens Chemotherapy Regimens Lung Cancer Notes from the editor These regimens are available on the Network website www.tvcn.org.uk. Any correspondence about the regimens should be addressed to: Sally Coutts,

More information

West of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021)

West of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) West of Scotland Cancer Network Chemotherapy Protocol Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) Indication Palliative chemotherapy for malignant mesothelioma of the pleura Eligibility

More information

Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer

Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer Background: A non-anthracycline based regimen for high-risk, HER 2 positive breast cancer in the adjuvant setting (BCIRG 006). Patient

More information

Regimen: Gemcitabine & Carboplatin for NSCLC

Regimen: Gemcitabine & Carboplatin for NSCLC Regimen: Gemcitabine & Carboplatin for NSCLC ICD10 codes Codes pre-fixed with C34. Indications Regimen details First-line chemotherapy for advanced (stage IIIB/IV) non-small cell lung cancer (NICE CG121)

More information

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine Capecitabine Capecitabine 1000-1250mg/m 2 oral TWICE daily for 14 days Until disease progression Capecitabine + Docetaxel Capecitabine 750-1000mg/m 2 oral TWICE daily for 14 days Up to 6 cycles Capecitabine

More information

West of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol

West of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol West of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol FEC-DH in the adjuvant treatment of Breast Cancer (BRWOS- 031/1) Indication Adjuvant chemotherapy for HER2+ve Early Breast Cancer Eligibility

More information

Breast Pathway Group AC (Doxorubicin / Cyclophosphamide) in Early Breast Cancer

Breast Pathway Group AC (Doxorubicin / Cyclophosphamide) in Early Breast Cancer Breast Pathway Group AC (Doxorubicin / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant treatment of breast cancer Regimen details: Doxorubicin 60mg/m 2 IV Day 1 Cyclophosphamide

More information

BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP)

BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP) BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP) Protocol Code Tumour Group Contact Physician UGUTIP Genitourinary Dr.

More information

NORDIC. Indication Mantle cell lymphoma (for patients suitable for subsequent chemotherapy with haematopoietic stem cell rescue)

NORDIC. Indication Mantle cell lymphoma (for patients suitable for subsequent chemotherapy with haematopoietic stem cell rescue) NORDIC C) CODOX (R) CODOX M/ (R) IVAC Indication Mantle cell lymphoma (for patients suitable for subsequent chemotherapy with haematopoietic stem cell rescue) ICD-10 code C83.13 Regimen details (R) maxi-chop

More information

Docetaxel, Carboplatin and Trastuzumab (TCH i.e. Taxotere Carboplatin, Herceptin ) for Early Breast Cancer

Docetaxel, Carboplatin and Trastuzumab (TCH i.e. Taxotere Carboplatin, Herceptin ) for Early Breast Cancer Regimen: Docetaxel, Carboplatin and Trastuzumab (TCH i.e. Taxotere Carboplatin, Herceptin ) for Early Breast Cancer Indication Approved for the treatment of early and locally advanced breast cancer in

More information

Guidelines for the Use of Anti-Emetics with Chemotherapy

Guidelines for the Use of Anti-Emetics with Chemotherapy Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting

More information

Thames Valley Cancer Network. Network Chemotherapy Protocols Breast Cancer

Thames Valley Cancer Network. Network Chemotherapy Protocols Breast Cancer Network Chemotherapy Protocols Breast Cancer Notes from the editor Thames Valley Cancer Network These protocols are available on the Network website www.tvcn.nhs.uk. Any correspondence about the protocols

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

CTD (Cyclophosphamide, Thalidomide and Dexamethasone)

CTD (Cyclophosphamide, Thalidomide and Dexamethasone) MCCN Ref MMCTD OPCS Proc X71.1 OPCS Del X73.1 Haematology Chemotherapy Protocol CTD (Cyclophosphamide, Thalidomide and Dexamethasone) Indications Multiple Myeloma (newly diagnosed and relapsed / refractory

More information

Out-Patient Chemotherapy for Lung Cancer

Out-Patient Chemotherapy for Lung Cancer Lung Cancer Out-Patient Chemotherapy for Lung Cancer Principles and practice JMAJ 46(12): 542 546, 2003 Shuichi YONEDA Director, Department of Pulmonary Medicine, Saitama Cancer Center Abstract: Recent

More information

London Cancer. Mesothelioma Lung Protocols

London Cancer. Mesothelioma Lung Protocols London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta

More information

About chemotherapy for lung cancer

About chemotherapy for lung cancer About chemotherapy for lung cancer This information is about chemotherapy for lung cancer. There are sections on What is chemotherapy? Chemotherapy for small cell lung cancer Chemotherapy for non-small

More information

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Indication: In combination with docetaxel in locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma

More information

Regimen: Fluorouracil, Epirubicin and Cyclophosphamide + Docetaxel (FEC/T) for Early Breast Cancer

Regimen: Fluorouracil, Epirubicin and Cyclophosphamide + Docetaxel (FEC/T) for Early Breast Cancer Regimen: Fluorouracil, Epirubicin and Cyclophosphamide + Docetaxel (FEC/T) for Early Breast Cancer Indication Adjuvant treatment for node positive early breast cancer This protocol is subject to local

More information

Chemotherapy for lung cancer

Chemotherapy for lung cancer This information is an extract from the booklet Understanding lung cancer. You may find the full booklet helpful. We can send you a free copy see page 8. Contents Chemoradiation Small cell lung cancer

More information

Adjuvant Chemotherapy 1. Vinorelbine-25/Cisplatin-80 (chemo alone) CTIS 1722 4 2. Gemcitabine-1250/Carboplatin-5AUC CTIS 1601 5

Adjuvant Chemotherapy 1. Vinorelbine-25/Cisplatin-80 (chemo alone) CTIS 1722 4 2. Gemcitabine-1250/Carboplatin-5AUC CTIS 1601 5 LUNG CANCER Section by: Dr Conrad Lewanski, Dr Danielle Power, Dr Tom Newsom-Davis Version; Lung Cancer Regimens v4.3 NWLCN 20Feb12 Section last reviewed: 1 st July 2011 Section last corrected: 20 th February

More information

AC-Docetaxel: Doxorubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer

AC-Docetaxel: Doxorubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer AC-Docetaxel: Doxubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer Indication: Neoadjuvant therapy f high risk and fit Breast Cancer patients, suitable f a taxane containing regimen AC Regimen

More information

Breast Cancer. Breast Cancer Page 1

Breast Cancer. Breast Cancer Page 1 Breast Cancer Summary Breast cancers which are detected early are curable by local treatments. The initial surgery will give the most information about the cancer; such as size or whether the glands (or

More information

Breast Pathway Group FEC(100)-Docetaxel: Fluorouracil / Epirubicin / Cyclophosphamide followed by Docetaxel in Early Breast Cancer

Breast Pathway Group FEC(100)-Docetaxel: Fluorouracil / Epirubicin / Cyclophosphamide followed by Docetaxel in Early Breast Cancer Breast Pathway Group FEC(100)-Docetaxel: Fluorouracil / Epirubicin / Cyclophosphamide followed by Docetaxel in Indication: Neoadjuvant or adjuvant therapy in node positive patients. Also considered in

More information

Emerging Drug List GEFITINIB

Emerging Drug List GEFITINIB Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:

More information

More than half of all lung cancer patients present with. New Combinations in the Treatment of Lung Cancer* A Time for Optimism

More than half of all lung cancer patients present with. New Combinations in the Treatment of Lung Cancer* A Time for Optimism New Combinations in the Treatment of Lung Cancer* A Time for Optimism Paul A. Bunn, Jr., MD; and Karen Kelly, MD Strides have been made in the treatment of lung cancer in the last decade that warrant a

More information

DT- PACE chemotherapy for myeloma

DT- PACE chemotherapy for myeloma Patient information DT- PACE chemotherapy for myeloma Your doctors have suggested that you are likely to benefit from chemotherapy treatment. They are recommending a standard form of treatment called DT-PACE

More information

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

Good symptom relief with palliative MVP (mitomycin-c, vinblastine and cisplatin) chemotherapy in malignant mesothelioma

Good symptom relief with palliative MVP (mitomycin-c, vinblastine and cisplatin) chemotherapy in malignant mesothelioma Annals of Oncology 9: 9-7, 998. 998 Khmer Academic Publishers. Printed in the Netherlands Original article Good symptom relief with palliative MVP (mitomycin-c, vinblastine and cisplatin) chemotherapy

More information

FEC-D Regimen. FEC-D+TRAS Regimen FEC-D FEC-D+TRAS. A - Regimen Name. Disease Site Breast. Adjuvant. Regimen Category. Evidence-Informed :

FEC-D Regimen. FEC-D+TRAS Regimen FEC-D FEC-D+TRAS. A - Regimen Name. Disease Site Breast. Adjuvant. Regimen Category. Evidence-Informed : Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended

More information

Adjuvant Chemotherapy After Complete Resection of Non-Small Cell Lung Cancer

Adjuvant Chemotherapy After Complete Resection of Non-Small Cell Lung Cancer REVIEW ARTICLE Adjuvant Chemotherapy After Complete Resection of Non-Small Cell Lung Cancer Eckart Laack, Carsten Bokemeyer, Dieter Kurt Hossfeld SUMMARY Introduction: In non-small cell lung cancer (NSCLC)

More information

Regimen : Fludarabine Cyclophosphamide Rituximab (FCR-oral)

Regimen : Fludarabine Cyclophosphamide Rituximab (FCR-oral) Regimen : Fludarabine Cyclophosphamide Rituximab (FCR-oral) Indication CLL 1st line as per NICE TAG 174 CLL (relapsed) as per NICE TAG 193 Regimen details Day Drug Dose Route Cycle 1 1 Rituximab 375mg/m

More information

BCCA Protocol for Primary Treatment of Metastatic or Recurrent Squamous Cancer of the Cervix with Bevacizumab, CARBOplatin and PACLitaxel

BCCA Protocol for Primary Treatment of Metastatic or Recurrent Squamous Cancer of the Cervix with Bevacizumab, CARBOplatin and PACLitaxel BCCA Protocol for Primary Treatment of Metastatic or Recurrent Squamous Cancer of the Cervix with Bevacizumab, CARBOplatin and PACLitaxel Protocol Code Tumour Group Contact Physician GOCXCATB Gynecologic

More information

Dr P Savage Date Review date: October 2015. Gemcitabine Regimens 1. Gemcitabine-1250/Cisplatin-70 D1+8 CTIS 1695 2

Dr P Savage Date Review date: October 2015. Gemcitabine Regimens 1. Gemcitabine-1250/Cisplatin-70 D1+8 CTIS 1695 2 BLADDER CANCER / TRANSITIONAL CELL CARCINOMA Section by: Dr Philip Savage, Professor Jonathan Waxman, Dr Alison Falconer, Dr Simon Stewart. Version: Bladder Cancer/TCC Regimens Approved v7.01 NWLCN 15Oct13

More information

What s New With HER2?

What s New With HER2? What s New With HER2? Trastuzumab emtansine and pertuzumab for metastatic breast cancer Lindsay Livingston Pharmacist CancerCare Manitoba October 3, 2014 Presenter Disclosure Faculty: Lindsay Livingston

More information

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, FACT SHEET BRANDED/GENERIC NAME: ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) ABRAXANE is an albumin-bound form of paclitaxel with a

More information

Hydration Protocol for Cisplatin Chemotherapy

Hydration Protocol for Cisplatin Chemotherapy Betsi Cadwaladr University Health Version: 1.3 CSPM2 Hydration Protocol for Cisplatin Chemotherapy Date to be reviewed: July 2018 No of pages: 9 Author(s): Tracy Parry-Jones Author(s) title: Lead Cancer

More information

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory

More information

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage

More information

PREMEDICATIONS: Agent(s) Dose Route Schedule

PREMEDICATIONS: Agent(s) Dose Route Schedule BCCA Protocol Summary for the Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and rituximab Protocol Code Tumour Group

More information

Treatment of Small Cell Lung Cancer

Treatment of Small Cell Lung Cancer Chapter 5 Treatment of Small Cell Lung Cancer Ariel Lopez-Chavez MD, MS Introduction There are two main types of lung cancer, non-small cell lung cancer and small cell lung cancer. 1 It is important that

More information

Regimen: Pegylated Liposomal Doxorubicin Hydrochloride (PLDH) (Caelyx ) and Carboplatin ( CALYPSO regimen)

Regimen: Pegylated Liposomal Doxorubicin Hydrochloride (PLDH) (Caelyx ) and Carboplatin ( CALYPSO regimen) Regimen: Pegylated Liposomal Doxorubicin Hydrochloride (PLDH) (Caelyx ) and Carboplatin ( CALYPSO regimen) Indications This is NOT a NICE-approved treatment. Please ensure that this regimen is locally

More information

Pre-HCT Treatment for Hodgkin s / Non-Hodgkin s Lymphoma

Pre-HCT Treatment for Hodgkin s / Non-Hodgkin s Lymphoma Pre-HCT Treatment for Hodgkin s / Non-Hodgkin s Lymphoma This appendix is intended to provide additional information on: Common pre-hct treatments for lymphoma, Lines of therapy, Cycles, and How to report

More information

Fludarabine based chemotherapy [Fludarabine, FC, FCR, FMD]

Fludarabine based chemotherapy [Fludarabine, FC, FCR, FMD] Approved Haematology Chemotherapy Protocol Fludarabine based chemotherapy [Fludarabine, FC, FCR, FMD] MCCN Ref OPCS Proc OPCS Del CLFLUD X70.5 X72.3 IV CLFC X70.4 X72.2 IV X73.1 O CLFCR X71.5 X72.1 LYFMD

More information

1.1 Title: Generic Chemotherapy Protocol Guidelines

1.1 Title: Generic Chemotherapy Protocol Guidelines 1.1 Title: Generic Chemotherapy Protocol Guidelines 1.2 Summary of the policy s objectives: This guidance is intended to be used by all health-care professionals involved in the prescribing and delivery

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

More information

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly

More information

Regimen : EOX (Epirubicin, Oxaliplatin and Capecitabine (Xeloda ))

Regimen : EOX (Epirubicin, Oxaliplatin and Capecitabine (Xeloda )) Regimen : EOX (Epirubicin, Oxaliplatin and Capecitabine (Xeloda )) Indication Regimen details Administration First line palliative treatment for locally advanced, inoperable oesophago-gastric cancer for

More information

The Role of Combination Chemotherapy in the Initial Management of Limited-Stage Small-Cell Lung Cancer

The Role of Combination Chemotherapy in the Initial Management of Limited-Stage Small-Cell Lung Cancer Evidence-based Series 7-13-1 Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) The Role of Combination Chemotherapy in the Initial Management of Limited-Stage

More information

Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail

Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail Indication: Neoadjuvant or adjuvant therapy for elderly and frail patients with breast

More information

Chemotherapy for non-small cell lung cancer

Chemotherapy for non-small cell lung cancer Chemotherapy for non-small cell lung cancer This information is an extract from the booklet Understanding lung cancer. You may find the full booklet helpful. We can send you a free copy see page 3. Contents

More information

NCCP Chemotherapy Protocol. Afatinib Monotherapy

NCCP Chemotherapy Protocol. Afatinib Monotherapy Afatinib Monotherapy INDICATIONS FOR USE: INDICATION Treatment of Epidermal Growth Factor Receptor (EGFR) TKI- naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS

More information

Controversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction:

Controversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction: Inoperable NSCLC Controversies in Management of Inoperable NSCLC Introduction: It is difficult to overemphasize the magnitude of lung cancer as Public Health Problem in our society. - In US, Lung cancer

More information

REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group Educational session Treatment of stage III non-small cell lung cancer (NSCLC) in

More information

non-small cell lung cancer

non-small cell lung cancer Thorax 1985;40:346-350 Cisplatin, vinblastine, and bleomycin in inoperable non-small cell lung cancer R STUART-HARRIS, RM FOX, D RAGHAVAN, AS COATES, D HEDLEY, JA LEVI, RL WOODS, MHN TATTERSALL From the

More information

1 PRACTICAL ISSUES IN CYTOTOXIC

1 PRACTICAL ISSUES IN CYTOTOXIC 1 PRACTICAL ISSUES IN CYTOTOXIC CHEMOTHERAPY USAGE Introduction Inthischapter, theprinciplesofcytotoxicchemotherapy treatment and the appropriate use of anticancer drugs, including some of the new targeted

More information

New Treatment Options for Breast Cancer

New Treatment Options for Breast Cancer New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of

More information

CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER. Walter Stadler, MD University of Chicago

CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER. Walter Stadler, MD University of Chicago CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER Walter Stadler, MD University of Chicago Chemotherapy Doctor Terms Drugs used to treat cancer Will attack cancer no matter where it is located

More information

Update on Small Cell Lung Cancer

Update on Small Cell Lung Cancer Welcome to Master Class for Oncologists Session 3: 2:45 PM - 3:30 PM Washington, DC March 28, 2009 Small Cell Lung Cancer: Best Practices & Recent Advances Speaker: Bruce E. Johnson, MD Professor of Medicine,

More information

CHEMOTHERAPY PROTOCOLS V10.1

CHEMOTHERAPY PROTOCOLS V10.1 CHEMOTHERAPY PROTOCOLS V10.1 Issue Date: 10 th July 2014 Page 1 of 42 Filename: MCHACPROTO Issue No: 10.1 CCC Chemotherapy Protocols Haematological Malignancies... 3 Hodgkins disease...3 Non-Hodgkins Lymphoma...5

More information

ADJUVANT TREATMENT CLINICAL EVALUATION NEOADJUVANT TREATMENT

ADJUVANT TREATMENT CLINICAL EVALUATION NEOADJUVANT TREATMENT te: Consider Clinical Trials as treatment options for eligible patients. Referral to a center with both pediatric oncology and orthopedic surgery is essential. CLINICAL EVALUATION This practice algorithm

More information

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT

More information

Effects of Chemotherapy on Quality of Life for Patients with Lung Cancer

Effects of Chemotherapy on Quality of Life for Patients with Lung Cancer CLINICAL STUDY Effects of Chemotherapy on Quality of Life for Patients with Lung Cancer Ahmet Bircan, MD 1 ; M. Bahad r Berktafl, MD 1 ; Hülya Bay z, MD 1 ; Nihal Baflay, MD 1 ; Sema Bircan, MD 2 ; Mine

More information

London Cancer Systemic Treatment for Breast Cancer

London Cancer Systemic Treatment for Breast Cancer London Cancer Systemic Treatment for Breast Cancer July 2013 Revise every 6 months Full review April 2015 Version 1.1 (January 2014 update) Contents 1. Neo-adjuvant or Primary Medical Treatment... 3 1.1.

More information

LUNG CANCER TREATMENT REGIMENS (Part 1 of 7)

LUNG CANCER TREATMENT REGIMENS (Part 1 of 7) LUNG CANCER TREATMENT S (Part 1 of 7) Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration,

More information

First-Line Palliative Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma with Cetuximab, Platinum, and 5 FU

First-Line Palliative Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma with Cetuximab, Platinum, and 5 FU Practice Guideline: Systemic Therapy Summary First-Line Palliative Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma with Cetuximab, Platinum, and 5 FU (Head & Neck Cetuximab, Platinum,

More information

Acute Lymphoblastic Leukemia in Children A Brief Review of the Internationally Available Protocols

Acute Lymphoblastic Leukemia in Children A Brief Review of the Internationally Available Protocols Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines Geneva, 29 September to 3 October 2008 Acute Lymphoblastic Leukemia in Children A Brief Review

More information

SMALL. 1-800-298-2436 LungCancerAlliance.org

SMALL. 1-800-298-2436 LungCancerAlliance.org Understanding series SMALL CELL LUNG CANCER 1-800-298-2436 LungCancerAlliance.org A guide for the patient I TABLE OF CONTENTS ANATOMY OF THE LUNGS The following image shows different parts that make up

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines

Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines North of England Cancer Network Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines Adult Oncology & Haematology Quality and safety for every patient every time For more information

More information

This 2-part article will discuss 9 anticancer. Commonly Used Chemotherapy Drugs Part 1. M e d i c a t i o n s. Clinician s Brief.

This 2-part article will discuss 9 anticancer. Commonly Used Chemotherapy Drugs Part 1. M e d i c a t i o n s. Clinician s Brief. M e d i c a t i o n s O N C O L O G Y Peer Reviewed Antony Moore, BVSc, MVSc, Diplomate ACVIM (Oncology) Veterinary Oncology Consultants, Sydney, Australia Commonly Used Chemotherapy Drugs Part 1 This

More information

TC Chemotherapy Regimen (Docetaxel + Cyclophosphamide)

TC Chemotherapy Regimen (Docetaxel + Cyclophosphamide) TC Chemotherapy Regimen (Docetaxel + Cyclophosphamide) TC is a regimen or treatment plan that includes a combination of chemotherapy drugs that your doctor prescribed for the treatment of your cancer.

More information

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015

More information

One milliliter concentrate for solution for infusion contains 1 mg topotecan (as hydrochloride).

One milliliter concentrate for solution for infusion contains 1 mg topotecan (as hydrochloride). 1. NAME OF THE MEDICINAL PRODUCT [nationally approved name] 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One milliliter concentrate for solution for infusion contains 1 mg topotecan (as hydrochloride).

More information

London Cancer Guideline- Dosing in Obesity

London Cancer Guideline- Dosing in Obesity London Cancer Guideline- Dosing in Obesity 1. Introduction Chemotherapy dosing in patients has historically been based on body surface area(bsa). (Freireich, 1966) Overweight and large patients have often

More information

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA) BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA) Protocol Code Tumour Group Contact Physician UBRAVKAD Breast Dr Stephen Chia ELIGIBILITY:

More information

DECISION AID SET. STAGE IV Non-Small Cell Lung Cancer (NSCLC)

DECISION AID SET. STAGE IV Non-Small Cell Lung Cancer (NSCLC) DECISION AID SET STAGE IV Non-Small Cell Lung Cancer (NSCLC) Dear Clinician: This set of DECISION AIDS is based on ASCO s Clinical Practice Guideline Update on Chemotherapy for Stage IV NSCLC (2009). ASCO

More information

TAXOTERE RECEIVES U.S. FDA APPROVAL FOR USE IN ADVANCED STOMACH CANCER

TAXOTERE RECEIVES U.S. FDA APPROVAL FOR USE IN ADVANCED STOMACH CANCER TAXOTERE RECEIVES U.S. FDA APPROVAL FOR USE IN ADVANCED STOMACH CANCER TAXOTERE -based regimen demonstrates a 23% reduction in the risk of mortality in patients with advanced stomach cancer Bridgewater,

More information

Management of Unresected Stage Ill Non-Small Cell Lung Cancer

Management of Unresected Stage Ill Non-Small Cell Lung Cancer Evidence-based Series 7-3 Version 2.2005 [TO BE UPDATED] A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Management of Unresected Stage Ill Non-Small Cell Lung

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER UNDERSTANDING SERIES SMALL CELL LUNG CANCER 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT I TABLE OF CONTENTS ANATOMY OF THE LUNGS The following image shows different parts that make up

More information

5-Fluorouracil & Radiotherapy for Adjuvant Oesophageal or Gastric Cancer (Modified Macdonald Protocol)

5-Fluorouracil & Radiotherapy for Adjuvant Oesophageal or Gastric Cancer (Modified Macdonald Protocol) 5-Fluorouracil & Radiotherapy for Adjuvant Oesophageal or Gastric Cancer (Modified Macdonald Protocol) Indication: Adjuvant Chemo-radiotherapy for patients with resectable adenocarcinoma of the stomach

More information

New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors

New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors DAVID S. ALBERTS, ROBERT T. DORR University of Arizona, Arizona Cancer Center, Tucson, Arizona, USA Key Words.

More information

Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment

Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment A Patient s Guide Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment Recommendations of the American Society of Clinical Oncology The American Society of Clinical Oncology (ASCO) is

More information

Guidelines for the Management of. Nausea and Vomiting in Cancer Patients

Guidelines for the Management of. Nausea and Vomiting in Cancer Patients Guidelines for the Management of Nausea and Vomiting in Cancer Patients Guidelines for the Management of Nausea and Vomiting in Cancer Patients Management of chemotherapy-induced nausea and vomiting includes

More information

Stage I, II Non Small Cell Lung Cancer

Stage I, II Non Small Cell Lung Cancer Stage I, II Non Small Cell Lung Cancer Best Results T1 (less 3 cm) N0 80% 5 year survival No Role Adjuvant Chemotherapy Radiation Therapy Reduces Local Recurrence No Improvement in Survival 1 Staging Mediastinal

More information

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured

More information

Nonanthracycline Containing Docetaxel-Based Combinations in Metastatic Breast Cancer

Nonanthracycline Containing Docetaxel-Based Combinations in Metastatic Breast Cancer nanthracycline Containing Docetaxel-Based Combinations in Metastatic Breast Cancer JOHN CROWN St. Vincent s Hospital, Dublin, Ireland Key Words. MBC Docetaxel Cisplatin Carboplatin Vinorelbine Gemcitabine

More information

EPITHELIAL OVARIAN CANCER

EPITHELIAL OVARIAN CANCER EPITHELIAL OVARIAN CANCER Executive Summary Epithelial ovarian cancer is the most common type of ovarian cancer and the most aggressive gynecological malignancy. Approximately 70% of patients are diagnosed

More information